120 related articles for article (PubMed ID: 8695265)
1. Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia.
Jung K; Lein M; Weiss S; Schnorr D; Henke W; Loening S
Eur J Cancer; 1996 Apr; 32A(4):627-30. PubMed ID: 8695265
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD44 variants in the serum of patients with urological malignancies.
Lein M; Jung K; Weiss S; Schnorr D; Loening SA
Oncology; 1997; 54(3):226-30. PubMed ID: 9143404
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients.
Stickeler E; Vogl FD; Denkinger T; Mobus VJ; Kreienberg R; Runnebaum IB
Int J Mol Med; 2000 Nov; 6(5):595-601. PubMed ID: 11029531
[TBL] [Abstract][Full Text] [Related]
4. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients.
Mayer S; zur Hausen A; Watermann DO; Stamm S; Jäger M; Gitsch G; Stickeler E
J Cancer Res Clin Oncol; 2008 Nov; 134(11):1229-35. PubMed ID: 18438684
[TBL] [Abstract][Full Text] [Related]
5. Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful?
Clements R; Penney MD; Etherington RJ; Griffiths GJ; Hughes H; Peeling WB
Prostate Suppl; 1992; 4():51-7. PubMed ID: 1374178
[TBL] [Abstract][Full Text] [Related]
6. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
[TBL] [Abstract][Full Text] [Related]
7. Serological evaluation of soluble CD44 in renal cancer.
Kan M; Kanayama H; Naruo S; Tsuji M; Kojima K; Kurokawa Y; Kagawa S
Jpn J Cancer Res; 1996 Nov; 87(11):1191-4. PubMed ID: 9045950
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.
Jung K; Nowak L; Lein M; Priem F; Schnorr D; Loening SA
Int J Cancer; 1997 Apr; 74(2):220-3. PubMed ID: 9133459
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis.
Lackner C; Moser R; Bauernhofer T; Wilders-Truschnig M; Samonigg H; Berghold A; Zatloukal K
Breast Cancer Res Treat; 1998 Jan; 47(1):29-40. PubMed ID: 9493973
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
11. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma.
Harn HJ; Ho LI; Shyu RY; Yuan JS; Lin FG; Young TH; Liu CA; Tang HS; Lee WH
J Clin Gastroenterol; 1996 Mar; 22(2):107-10. PubMed ID: 8742647
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
14. Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features.
Zalewski B
World J Gastroenterol; 2004 Feb; 10(4):583-5. PubMed ID: 14966921
[TBL] [Abstract][Full Text] [Related]
15. PR92 antigen in human prostate fluid: elevated levels in prostate cancer.
Carlin BI; Marachie J; Venegas MF; Schaeffer AJ; Shaw N; Hass GM; Rademaker AW; Lee C; Grayhack JT
Prostate; 1994 Sep; 25(3):156-61. PubMed ID: 7520579
[TBL] [Abstract][Full Text] [Related]
16. Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.
Fawzy MS; Mohamed RH; Elfayoumi AR
Med Oncol; 2015 Mar; 32(3):74. PubMed ID: 25698533
[TBL] [Abstract][Full Text] [Related]
17. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
Shannon BA; Cohen RJ; Garrett KL
BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
[TBL] [Abstract][Full Text] [Related]
18. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
[TBL] [Abstract][Full Text] [Related]
19. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
20. Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostate and benign prostatic hyperplasia.
Wolff JM; Stephenson RN; Chisholm GD; Habib FK
Eur J Cancer; 1995; 31A(3):339-41. PubMed ID: 7540402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
